← Eichor
Study identifier: NCT07567625 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)

Condition: Acute Myocardial Infarction (AMI) · ST-Segment Elevation Myocardial Infarction(STEMI) · Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)  ·  Sponsor: Harbin Medical University

PhaseNA
Planned participants2000
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study is a prospective, multicenter, open-label, non-inferiority, randomized controlled trial. A total of 2,000 patients with STEMI (\<24 hours or 7-14 days) or NSTEMI will be recruited from at least 20 centers in China. Eligible patients must have residual DS \< 70% at the culprit lesion assessed by QCA, with optional thrombus aspiration, and TIMI flow of grade 3. Patients will be randomly assigned in a 1:1 ratio to the experimental group or the control group. The planned enrollment period is 36 months, and all patients will be followed up for at least 12 months after randomization, with continued follow-up until the end of the study. The primary outcome is the first occurrence of TLF after randomization, defined as the composite of cardiovascular death, target vessel myocardial infarction, ischemia-driven target lesion revascularization. The study aims to verify whether guideline-recommended standard medical therapy is non-inferior to DES implantation combined with guideline-recommended standard medical therapy in AMI patients with non-severe coronary artery stenosis. A total of 120 participants (60 in the experimental group and 60 in the control group) enrolled at the Second Affiliated Hospital of Harbin Medical University were included in the functional substudy. Using Abbott Pressure Wire™X pressure wire test functional indicators, and explore the incidence of coronary microvascular dysfunction (CMD) as assessed by the index of microcirculatory resistance (IMR) in …

This description comes directly from the study's public registry record.

Talk to the study team

Jingbo Hou, Ph.D.  ·  13303609625  ·  jingbohou@163.com

Bo Yu, Ph.D.  ·  yubodr@163.com

Always discuss trial participation with your own doctor first.

Locations (48)

The Second Affiliated Hospital of Harbin Medical UniversityHarbin, Heilongjiang, ChinaRecruiting
Beijing Luhe Hospital Affiliated to Capital Medical UniversityBeijing, ChinaNot Yet Recruiting
Fuwai Hospital, Chinese Academy of Medical SciencesBeijing, ChinaNot Yet Recruiting
Cangzhou Central HospitalCangzhou, ChinaNot Yet Recruiting
Chengde Medical College Affiliated HospitalChengde, ChinaNot Yet Recruiting
Sichuan Provincial People's HospitalChengdu, ChinaNot Yet Recruiting
The Central Hospital Affiliated to Dalian University of TechnologyDalian, ChinaNot Yet Recruiting
The First Affiliated Hospital of Dalian Medical UniversityDalian, ChinaNot Yet Recruiting
The Second Affiliated Hospital of Dalian Medical UniversityDalian, ChinaNot Yet Recruiting
Daqing Oilfield General HospitalDaqing, ChinaNot Yet Recruiting
The Fourth Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNot Yet Recruiting
The Third Xiangya Hospital of Central South UniversityHunan, ChinaNot Yet Recruiting

+ 36 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07567625